| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Zenocutuzumab
CAS:1969309-56-5
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Zenocutuzumab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 15002144251 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Zenocutuzumab
CAS:1969309-56-5
Purity:97% Package:5mg/RMB 8460;1mg/RMB 3980;10mg/RMB 11300
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Zenocutuzumab (DHC09609)
CAS:1969309-56-5
Purity:PAGE:>95% Package:100ug;1mg
|
|
| | Zenocutuzumab Basic information |
| Product Name: | Zenocutuzumab | | Synonyms: | Zenocutuzumab;Research Grade Zenocutuzumab (DHC09609);Research Grade Zenocutuzumab;Immunoglobulin G1, bispecific, anti-(human epidermal growth factor receptors, HER2 and HER3) (humanized clone MCLA-128 γ1-chain), disulfide with humanized clone MCLA-128 light chain, dimer (ACI) | | CAS: | 1969309-56-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Zenocutuzumab Structure]() |
| | Zenocutuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Zenocutuzumab Usage And Synthesis |
| Uses | Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3[1]. | | in vivo | Zenocutuzumab (2.5-25 mg/kg; i.p.; once weekly; for 28 days) causes a statistically significant reduction of growth, including tumor regression[1]. | Animal Model: | 6 to 12-week-old female NSG (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors[1]. | | Dosage: | 2.5 mg/kg, 8 mg/kg, or 25 mg/kg | | Administration: | i.p.; once weekly; for 28 days | | Result: | Blocked growth of lung and ovarian cancer PDX models. |
| | References | [1] Alison M Schram, et al. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 May 2;12(5):1233-1247. DOI:10.1158/2159-8290.CD-21-1119 |
| | Zenocutuzumab Preparation Products And Raw materials |
|